Tae Min Kim, MD, PhD1*, Katharine L. Lewis2, Juan Pablo Alderuccio, MD3, Hun Ju Lee, MD4, Enrico Derenzini, MD, PhD5*, Pier Luigi Zinzani, MD, PhD6, Marco Ladetto, MD7, Elizabeth H. Phillips8*, Hervé Ghesquieres, MD, PhD9*, François Lemonnier10*, Franck Morschhauser11, Ana Sureda Balari12, Antonia Rodriguez Izquierdo13*, Peter Borchmann, MD14, Matthew Weinstock15*, Jakub Svoboda, MD16, Emma Dean17*, Jelena Urosevic17*, Stefanie Meyer18*, Robert Chen19*, Richard Olsson20*, Kaitlyn Beyfuss21* and Graham P. Collins22
1Seoul National University Hospital, Seoul, Korea, Republic of (South)
2Linear Clinical Research, Sir Charles Gairdner Hospital and the University of Western Australia, Perth, Western Australia, Australia
3Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
5European Institute of Oncology, Milan, Italy
6University of Bologna, Istituto Di Ematologia, Bologna, Italy
7Ospedale Civile Ss. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
8University of Manchester, Christie NHS Foundation Trust and Division of Cancer Sciences, Manchester, United Kingdom
9Hospital Lyon Sud, Lyon, France
10Hopital Henri Mondor, Créteil, France
11Centre Hospitalier Universitaire de Lille - Hopital Claude Huriez, Lille, France
12Instituto Catalán de Oncología - Hospital Duran i Reynals, Barcelona, Spain
13Hospital Universitario 12 de Octubre, Madrid, Spain
14Universitätsklinikum Köln, Cologne, Germany
15Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA
16Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
17Oncology R&D, AstraZeneca, Cambridge, United Kingdom
18Hematology R&D, AstraZeneca, Boston, MA
19Hematology R&D, AstraZeneca, Cambridge, United Kingdom
20Hematology R&D, AstraZeneca, Mölndal, Sweden
21Hematology R&D, AstraZeneca, Mississauga, ON, Canada
22Oxford Cancer and Haematology Centre, Oxford, United Kingdom